Gallbladder cancer: epidemiology and outcome

Rajveer Hundal, Eldon A Shaffer, Rajveer Hundal, Eldon A Shaffer

Abstract

Gallbladder cancer, though generally considered rare, is the most common malignancy of the biliary tract, accounting for 80%-95% of biliary tract cancers. An early diagnosis is essential as this malignancy progresses silently with a late diagnosis, often proving fatal. Its carcinogenesis follows a progression through a metaplasia-dysplasia-carcinoma sequence. This comprehensive review focuses on and explores the risks, management, and outcomes for primary gallbladder carcinoma. Epidemiological studies have identified striking geographic and ethnic disparities - inordinately high occurrence in American Indians, elevated in Southeast Asia, yet quite low elsewhere in the Americas and the world. Age, female sex, congenital biliary tract anomalies, and a genetic predisposition represent important risk factors that are immutable. Environmental triggers play a critical role in eliciting cancer developing in the gallbladder, best exemplified by cholelithiasis and chronic inflammation from biliary tract and parasitic infections. Mortality rates closely follow incidence; those countries with the highest prevalence of gallstones experience the greatest mortality from gallbladder cancer. Vague symptoms often delay the diagnosis of gallbladder cancer, contributing to its overall progression and poor outcome. Surgery represents the only potential for cure. Some individuals are fortunate to be incidentally found to have gallbladder cancer at the time of cholecystectomy being performed for cholelithiasis. Such an early diagnosis is imperative as a late presentation connotes advanced staging, nodal involvement, and possible recurrence following attempted resection. Overall mean survival is a mere 6 months, while 5-year survival rate is only 5%. The dismal prognosis, in part, relates to the gallbladder lacking a serosal layer adjacent to the liver, enabling hepatic invasion and metastatic progression. Improved imaging modalities are helping to diagnose patients at an earlier stage. The last decade has witnessed improved outcomes as aggressive surgical management and preoperative adjuvant therapy has helped prolong survival in patients with gallbladder cancer. In the future, the development of potential diagnostic markers for disease will yield screening opportunities for those at risk either with ethnic susceptibility or known anatomic anomalies of the biliary tract. Meanwhile, clarification of the value of prophylactic cholecystectomy should provide an opportunity for secondary prevention. Primary prevention will arrive once the predictive biomarkers and environmental risk factors are more clearly identified.

Keywords: anomalous junction of the pancreaticobiliary duct; cholecystectomy; cholelithiasis; gallbladder polyp; gallstones; incidence; primary sclerosing cholangitis.

Figures

Figure 1
Figure 1
Gallbladder cancer incidence in the world. Note: Gallbladder cancer incidence rates are highest among certain ethnicities, particularly South American Indians and East Indian (northern India) females. Statistics derived from Cancer Incidence in Five Continents, Vol IX.10 This figure is adapted with permission from Stinton LM, Shaffer EA. Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer. Gut Liver. 2012;6(2):172–187. Abbreviations: GB, gallbladder; N, North; S, South.
Figure 2
Figure 2
Gallbladder cancer incidence and gallstone prevalence in high-risk populations. Note: Both gallbladder cancer incidence and gallstone prevalence are elevated in certain ethnicities, highlighting gallstones as a major risk factor for gallbladder cancer.
Figure 3
Figure 3
Gallbladder cancer staging and histology. Notes: Histology courtesy of Dr S Urbanski, Department of Pathology, University of Calgary. Tumor invasion (T) largely drives the staging criteria for gallbladder cancer. Regional lymph nodes (N) and distant metastasis (M) further advance staging and worsen the overall prognosis.
Figure 4
Figure 4
The 5-year relative survival (all ages, all races, both sexes, 1975–2005) for gallbladder cancer in the USA. Notes: The added trend line highlights the improving survival rates for individuals diagnosed with gallbladder cancer. (y =0.2295x −444.2; R2=0.43366).

References

    1. Lazcano-Ponce EC, Miquel JF, Muñoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA: Cancer J Clin 2001. 2001;51(6):349–364.
    1. Sheth S, Bedford A, Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol. 2000;95(6):1402–1410.
    1. Duffy A, Capanu M, Abou-Alfa GK, et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC) J Surg Oncol. 2008;98(7):485–489.
    1. Levy AD, Murakata LA, Rohrmann CA., Jr Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics. 2001;21(2):295–314. questionnaire, 549–555.
    1. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004;4(9):695–706.
    1. Surveillance, Epidemiology and End-Results Program (SEER) The Four Most Common Cancers for Different Ethnic Populations 2013. Bethesda, MD: National Cancer Institute; 2013.
    1. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591–1602.
    1. Konstantinidis IT, Deshpande V, Genevay M, et al. Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. Arch Surg. 2009;144(5):441–447.
    1. Gupta P, Agarwal A, Gupta V, Singh PK, Pantola C, Amit S. Expression and clinicopathological significance of estrogen and progesterone receptors in gallbladder cancer. Gastrointest Cancer Res. 2012;5(2):41–47.
    1. Curado MP, Edwards B, Shin HR, et al., editors. Cancer Incidence in Five Continents. IX. Lyon: International Agency for Research on Cancer; 2007.
    1. Surveillance, Epidemiology End-Results Program (SEER) The Four Most Common Cancers for Different Ethnic Populations 2013. Bethesda, MD: National Cancer Institute; 2013.
    1. Zatonski WA, Lowenfels AB, Boyle P, et al. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst. 1997;89(15):1132–1138.
    1. Sampliner RE, Bennett PH, Comess LJ, Rose FA, Burch TA. Gallbladder disease in Pima Indians. Demonstration of high prevalence and early onset by cholecystography. N Engl J Med. 1970;283(25):1358–1364.
    1. Everhart JE, Yeh F, Lee ET, et al. Prevalence of gallbladder disease in American Indian populations: findings from the Strong Heart Study. Hepatology. 2002;35(6):1507–1512.
    1. Miquel JF, Covarrubias C, Villaroel L, et al. Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology. 1998;115(4):937–946.
    1. Singh V, Trikha B, Nain C, Singh K, Bose S. Epidemiology of gallstone disease in Chandigarh: a community-based study. J Gastroenterol Hepatol. 2001;16(5):560–563.
    1. Koea J, Phillips A, Lawes C, Rodgers M, Windsor J, McCall J. Gall bladder cancer, extrahepatic bile duct cancer and ampullary carcinoma in New Zealand: Demographics, pathology and survival. ANZ J Surg. 2002;72(12):857–861.
    1. Stringer MD, Fraser S, Gordon KC, Sharples K, Windsor JA. Gallstones in New Zealand: composition, risk factors and ethnic differences. ANZ J Surg. 2013;83(7–8):575–580.
    1. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012;6(2):172–187.
    1. Lowenfels AB, Walker AM, Althaus DP, Townsend G, Domellöf L. Gallstone growth, size, and risk of gallbladder cancer: an interracial study. Int J Epidemiol. 1989;18(1):50–54.
    1. Diehl AK. Gallstone size and the risk of gallbladder cancer. JAMA. 1983;250(17):2323–2326.
    1. Shaffer EA. Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006;20(6):981–996.
    1. Shaffer EA. Gallbladder cancer: the basics. Gastroenterol Hepatol (N Y) 2008;4(10):737–741.
    1. Le MD, Henson D, Young H, Albores-Saavedra J. Is gallbladder cancer decreasing in view of increasing laparoscopic cholecystectomy? Ann Hepatol. 2011;10(3):306–314.
    1. Rashid A, Ueki T, Gao YT, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res. 2002;8(10):3156–3163.
    1. Berk RN, Armbuster TG, Saltzstein SL. Carcinoma in the porcelain gallbladder. Radiology. 1973;106(1):29–31.
    1. Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: a relationship revisited. Surgery. 2001;129(6):699–703.
    1. Cunningham SC, Alexander HR. Porcelain gallbladder and cancer: ethnicity explains a discrepant literature? Am J Med. 2007;120(4):e17–e18.
    1. Schnelldorfer T. Porcelain gallbladder: a benign process or concern for malignancy? J Gastrointest Surg. 2013;17(6):1161–1168.
    1. Kumar S. Infection as a risk factor for gallbladder cancer. J Surg Oncol. 2006;93(8):633–639.
    1. Gonzalez-Escobedo G, Marshall JM. Chronic and acute infection of the gall bladder by Salmonella Typhi: understanding the carrier state. Nature Reviews: Microbiology. 2011 Jan;9(1):9–14.
    1. Saetta AA. K-ras, p53 Mutations, and Microsatellite Instability (MSI) in Gallbladder Cancer. J Surg Oncol. 2006 Jun 15;93(8):644–649.
    1. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011 Oct 28;54(5):1842–1852.
    1. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC. Prevalence and Risk Factors for Gallbladder Neoplasia in Patients With Primary Sclerosing Cholangitis: Evidence for a Metaplasia-Dysplasia-Carcinoma Sequence. American Journal of Surgical Pathology. 2007 Jun 1;31(6):907–913.
    1. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010 Feb;51(2):660–678.
    1. European Association for the Stud EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. Journal of Hepatology. 2009 Aug;51(2):237–267.
    1. Pandey M. Environmental pollutants in gallbladder carcinogenesis. J Surg Oncol. 2006;93(8):640–643.
    1. Lubin JH, Boice JD, Edling C, Hornung RW, Howe GR, Kunz E, et al. Lung Cancer in Radon-Exposed Miners and Estimation of Risk From Indoor Exposure. Journal of the National Cancer Institute. 1995 Jun 7;87(11):817–827.
    1. Darby SC, Whitley E, Howe GR, Hutchings SJ, Kusiak RA, Lubin JH, et al., editors. Radon and Cancers Other Than Lung Cancer in Underground Miners: a Collaborative Analysis of 11 Studies. Journal of the Cancer Institute. 1995 Mar 1;87(5):378–384.
    1. Jain K, Sreenivas V, Velpandian T, Kapil U, Garg PK. Risk factors for gallbladder cancer: A case-control study. Int J Cancer. 2012 Sep 21;132(7):1660–1666.
    1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, Obesity, and Mortlity from Cancer in a Prospectively Studied Cohort of U.S. Adults. The New England Journal of Medicine. 2003 Apr 24;348(17):1625–1638.
    1. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for gallbladder cancer across the world. MHPB. 2008;10(5):327–331.
    1. Wolin KY, Carson K, Colditz GA. Obesity and Cancer. The Oncologist. 2010 Jun 24;15(6):556–565.
    1. Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: a meta-analysis. British Journal of Cancer. 2007 May 7;96(9):1457–1461.
    1. Lai HC, Chang SN, Lin CC, Chen CC, Chou JW, Peng CY, et al. Does diabetes mellitus with or without gallstones increase the risk of gallbladder cancer? Results from a population-based cohort study. J Gastroenterol. 2013 Jul;48(7):856–865.
    1. Myers RP, Shaffer EA. Gallbladder polyps: Epidemiology, natural history and management. Canadian Journal of Gastroenterology. 2002 Mar;16(3):187–194.
    1. Gallahan WC, Conway JD. Diagnosis and Management of Gallbladder Polyps. Gastroenterology & Hepatology. 2010 Jun;39(2):359–367.
    1. Jorgensen T, Jensen KH. Polyps in the gallbladder. A prevalence study. Scandinavian Journal of Gastroenterology. 1990 Mar;25(3):281–286.
    1. Roa I, de Aretxabala X, Morgan R, Molina R, Araya JC, Roa J, et al. Clinicopathological features of gallbladder polyps and adenomas. Revista Medica de Chile. 2004 Jun;132(6):673–679.
    1. Terzi C, Sokmen S, Seckin S, Albayrak L, Ugurlu M. Polypoid Lesions of the Gallbladder: Report of 100 cases with special reference to operative indications. Surgery. 2000 Jun;127(6):622–627.
    1. Nuzzo G, Clemente G, Cadeddu F, Ardito F, Ricci R, Vecchio FM. Papillary carcinoma of the gallbladder and anomalous pancreaticobiliary junction. Report of three cases and review of the literature. Hepatogastroenterology. 2005 Jul-Aug;52(64):1034–1038.
    1. Nomura T, Shirai Y, Sandoh N, Nagakura S, Hatakeyama K. Cholangiographic criteria for anomalous union of the pancreatic and biliary ducts. Gastrointestinal Endoscopy. 2002 Feb;55(2):204–208.
    1. Dutta U, Nagi B, Garg PK, Sinha SK, Singh K, Tandon RK. Patients with gallstones develop gallbladder cancer at an earlier age. European Journal of Cancer Prevention. 2005 Aug;14(4):381–385.
    1. Dutta U. Gallbladder cancer: Can newer insights improve the outcome? Journal of Gastroenterology and Hepatology. 2012 Mar 22;27(4):642–653.
    1. Itol T, Watanabe H, Ajioka Y, Oohashl Y, Takei K, Nishikura K, et al. APC, K-ras codon 12 mutations and p 5 3 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Pathology International. 1996 May;46(5):333–340.
    1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual. Springer; 2010.
    1. Ouchi K, Mikuni J. Laparoscopic cholecystectomy for gallbladder carcinoma: results of a Japanese survey of 498 patients. Journal of Hepatobiliary and Pancreatic Surgery. 2002;9(2):256–260.
    1. Boutros C, Gary M, Baldwin K, Somasundar P. Gallbladder cancer: Past, present and an uncertain future. Surg Oncol. 2012;21(4):e183–e191.
    1. Gallbladder Cancer: Comparison of Patients Presenting Initially for Definitive Operation With Those Presenting After Prior Noncurative Intervention. Ann Surg. 2000;232(4):557–569.
    1. Goldin RD, Roa JC. Gallbladder cancer: a morphological and molecular update. Histopathology. 2009;55(2):218–229.
    1. Jayaraman S, Jarnagin WR. Management of Gallbladder Cancer. Gastroenterol Clin North Am. 2010;39(2):331–342.
    1. Joo I, Lee JY, Kim JH, Kim SJ, Kim MA, Han JK, Choi BI. Differentiation of adenomyomatosis of the gallbladder from early-stage, wall-thickening-type gallbladder cancer using high-resolution ultrasound. Eur Radiol. 2012;23(3):730–8.
    1. Kim HJ, Lee SK, Jang JW, et al. Diagnostic role of endoscopic ultrasonography-guided fine needle aspiration of gallbladder lesions. Hepatogastroenterology. 2012;59(118):1691–1695.
    1. Kumaran V, Gulati MS, Paul SB, Kumar Pande G, Sahni P, Chattopadhyay TK. The role of dual-phase helical CTin assessing resectability of carcinoma of the gallbladder. Eur Radiol. 2002;12(8):1993–1999.
    1. Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg. 2007;11(5):671–681.
    1. Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, Jarnagin WR. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008;206(1):57–65.
    1. Pilgrim CHC, Usatoff V, Evans P. Consideration of anatomical structures relevant to the surgical strategy for managing gallbladder carcinoma. Eur J Surg Oncol. 2009;35(11):1131–1136.
    1. Pilgrim C, Usatoff V, Evans PM. A review of the surgical strategies for the management of gallbladder carcinoma based on T stage and growth type of the tumour. Eur J Surg Oncol. 2009;35(9):903–907.
    1. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
    1. Hyder O, Dodson RM, Sachs T, Weiss M, Mayo SC, Choti MA, et al. Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: A propensity score–matched Surveillance, Epidemiology, and End Results analysis. Surgery. 2013:pili. S0039-6060(13)00288–2.
    1. Aaronson S. Growth Factors and Cancer. Science. 1991;254(5035):1146–1153.
    1. Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavolloni G, Migliardi G, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliarytract and gallbladder carcinomas. BMC Cancer. 2010;10:631.
    1. Ito H, Ito K, D’Angelica M, et al. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Ann Surg. 2011;254(2):320–325.
    1. Pawlik TM, Gleisner AL, Vigano L, et al. Incidence of Finding Residual Disease for Incidental Gallbladder Carcinoma: Implications for Re-resection. J Gastrointest Surg. 2007;11(11):1478–86. discussion 1486–7.

Source: PubMed

3
Tilaa